10-Q: Envoy Medical Reports Q1 2025 Financial Results, Cites Progress on Acclaim Cochlear Implant Clinical Trial

Envoy Medical reports a net loss for Q1 2025, but highlights progress with its Acclaim Cochlear Implant clinical trial and ongoing development efforts.

Summary

• Envoy Medical, Inc., a hearing health company, reported its financial results for the quarter ended March 31, 2025.
• The company is focused on developing innovative medical technologies, including the Acclaim Cochlear Implant (CI).
• The Acclaim CI pivotal clinical study began in October 2024, with seven investigational sites selected.
• Five of the seven sites have received Institutional Review Board (IRB) approvals and been successfully activated.
• The first two Acclaim CI surgeries took place in February 2025, and all 10 patients in the first stage were implanted by mid-April.
• Six of the 10 patients have been activated.
• Envoy Medical is targeting expansion into the second stage of the clinical trial in the fourth quarter of 2025 or the first quarter of 2026.
• The company anticipates obtaining the FDA's decision on their Premarket Approval (PMA) application within the second half of 2027 or the first half of 2028.
• Net revenues for Q1 2025 were $46,000, compared to $59,000 for Q1 2024.
• The net loss for Q1 2025 was $5.0 million, compared to a net loss of $6.3 million for Q1 2024.
• Research and development expenses for Q1 2025 were $2.7 million, compared to $2.4 million for Q1 2024.
• As of March 31, 2025, Envoy Medical had $5.3 million in cash.
• The company expects to continue to incur net losses for the foreseeable future.
• Management believes that its existing cash balances combined with future capital raises through debt and equity and cash receipts from product sales will be sufficient to fund ongoing operations through at least one year from the date the condensed consolidated financial statements are issued.

Sentiment

Score: 6

Explanation: The document presents a mixed sentiment. While the company is making progress on its key product development and has reduced its net loss, it is still operating at a loss and faces significant risks and uncertainties. The presence of material weaknesses in internal control over financial reporting is also a concern.

Positives

• The net loss decreased from $6.3 million in Q1 2024 to $5.0 million in Q1 2025.
• Progress is being made on the Acclaim CI clinical trial, with the first stage fully enrolled and activation underway.
• The company has cash reserves of $5.3 million.
• Management believes that its existing cash balances combined with future capital raises through debt and equity and cash receipts from product sales will be sufficient to fund ongoing operations through at least one year from the date the condensed consolidated financial statements are issued.

Negatives

• Net revenues decreased from $59,000 in Q1 2024 to $46,000 in Q1 2025.
• The company continues to incur net losses and expects this to continue for the foreseeable future.
• The company has a accumulated deficit of $291.0 million as of March 31, 2025.
• The company's auditor has raised substantial doubt about the company's ability to continue as a going concern.

Risks

• The Acclaim CI has not yet been approved for sale, and there is no guarantee that it will receive FDA approval.
• The company's future success depends on obtaining regulatory approval and successfully commercializing the Acclaim CI.
• The company may need to raise additional capital to fund its operations, and there is no guarantee that it will be able to do so on favorable terms.
• The company faces competition in the medical device industry.
• The company's business and financial performance are impacted by macroeconomic conditions.
• The company does not maintain a sufficient complement of personnel with accounting knowledge, experience and training to appropriately analyze, record and disclose certain accounting matters to provide reasonable assurance of preventing material misstatements.
• The Companys management does not implement a formal risk assessment that addresses risks relevant to financial reporting objectives, including cybersecurity and fraud risks.
• The Company has not designed, documented and maintained formal accounting policies, procedures and controls over significant accounts and disclosures to achieve complete, accurate and timely financial accounting, reporting and disclosures, including segregation of duties and adequate controls related to the preparation, posting, modification and review of journal entries, and the accounting treatment of complex transactions, including fair value measurement under U.S. GAAP.
• The Company has not designed and maintained effective controls over certain information technology general controls for information systems that are relevant to the preparation of its condensed consolidated financial statements, including ineffective controls around user access and segregation of duties.

Future Outlook

Envoy Medical expects to continue to incur net losses for the foreseeable future as it continues its development of the Acclaim CI and seeks the necessary regulatory approvals. The company anticipates that its expenses will increase significantly in connection with its ongoing activities.

Management Comments

• Management believes that its existing cash balances combined with future capital raises through debt and equity and cash receipts from product sales will be sufficient to fund ongoing operations through at least one year from the date the condensed consolidated financial statements are issued.

Industry Context

Envoy Medical is operating in the hearing health industry, specifically targeting the cochlear implant market. The company believes that its fully implanted Acclaim CI offers a unique approach compared to existing cochlear implants, potentially disrupting the market. The company's first product, the Esteem FI-AMEI, received FDA approval in 2010 and remains the only FDA approved fully implanted hearing device in the US market.

Comparison to Industry Standards

• The report does not provide specific comparisons to industry standards or competitors.
• However, it mentions the established market acceptance and reimbursement pathways for cochlear implants, suggesting that Envoy Medical aims to leverage these existing structures with its Acclaim CI.
• The company's focus on a fully implanted design differentiates it from competitors offering traditional cochlear implants with external components.

Legal Proceedings

• The Company, Whitney Haring-Smith, Daniel Hirsch, and Anzu SPAC GP I LLC were named as defendants in a complaint filed by Atlas Merchant Capital SPAC Fund I LP in the Delaware Court of Chancery.
• Atlas alleges that it was not allowed to redeem its shares of the Company's Common Stock and that Defendants acted to prevent Atlas's attempt to redeem its shares.
• Atlas asserts damages in the amount of approximately $9.4 million, preand post-judgment interest, costs, and reasonable attorneys fees.
• The Company believes that the lawsuit is meritless and has been defending this matter vigorously.

Related Party Transactions

• The Company leases its headquarters office space in Minnesota from a company owned by a stockholder.
• The Company received Term Loans from the stockholder during 2024 and 2025.
• The Company has a shared services arrangement with a company that is indirectly owned by the stockholder, for certain support services used in the course of business.

Stakeholder Impact

• Shareholders: The company's continued losses and need for additional capital may dilute existing shareholders' ownership.
• Employees: The company's ability to continue operations and develop new products impacts job security and potential for growth.
• Customers: The development of the Acclaim CI could provide a new treatment option for individuals with severe to profound sensorineural hearing loss.
• Suppliers: The company's reliance on third-party suppliers and manufacturers creates a dependency that could be disrupted.
• Creditors: The company's ability to repay its debts depends on its ability to generate revenue and raise capital.

Next Steps

• Continue clinical trials for the Acclaim CI product candidate.
• Seek additional regulatory and marketing approvals in jurisdictions outside the United States.
• Establish a sales, marketing and distribution infrastructure to commercialize our product candidate.
• Rely on our third-party suppliers and manufacturers to obtain adequate supply of materials and components for our products.
• Seek to identify, assess, acquire, license, and/or develop other product candidates and subsequent generations of our current product candidate.
• Seek to maintain, protect, and expand our intellectual property portfolio.
• Seek to identify, hire, and retain additional skilled personnel.
• Create additional infrastructure to support our operations as a public company and our product candidate development and planned future commercialization efforts.

Key Dates

Keywords

Acclaim Cochlear Implant, Cochlear Implant, Esteem FI-AMEI, Clinical Trial, FDA Approval, Financial Results, Hearing Loss, Envoy Medical